Methods | Institutional review board approval was obtained from the Massachusetts Eye and Ear Infirmary. From billing records at the Massachusetts Eye and Ear Infirmary (MEEI) in Boston, we identified charges for visits between January 1, 2009, and December 31, 2013, on which MEEI health care practitioners reported a first visit for BPPV, defined as billing by the practitioner for either Current Procedural Terminology code 95992 or International Classification of Diseases, Ninth Revision code 386.11. To avoid repeatedly counting treatments of 1 bout of BPPV, we included only the first occurrence of either of these codes. We defined pooled BPPV visits as the total number of BPPV visits for a particular calendar month, summing over the 5 years investigated. We defined average early spring BPPV visits (AES-BPPV) as the mean of pooled BPPV visits for March, April, and May. Average nonearly spring BPPV visits (ANES-BPPV) was defined as the mean of pooled BPPV visits for the 9 months other than March, April, and May. In addition, we requested data on the total volume of otology and laryngology clinic and emergency department encounters for the period investigated. We defined pooled total visits as the total of otology and laryngology clinic and emergency department visits for a particular calendar month, summing over the 5 years investigated. We defined average early spring total visits (AES-Total) as the mean of pooled total visits for March, April, and May. Average non-early spring total visits (ANES-Total) was defined as the mean of pooled total visits for the 9 months other than March, April, and May. Statistical comparisons were made, using a 2-tailed t test, assuming unequal variances.
Results | There were 956 visits for BPPV during the 5 years, yielding an mean of 191 patients per year. All but 1 of these BPPV visits occurred either in the otology and laryngology clinic or in the emergency department. The AES-BPPV was 91.3 (SD 5.5). In contrast, ANES-BPPV was 75.8 (SD 8.4) ( Figure) . The difference between AES-BPPV and ANES-BPPV was statistically significant (P = .01). During the 5-year period investigated, the AES-Total was 24 525, and the ANES-Total was 22 819. This difference was not statistically significant (P = .05).
Discussion | The number of BPPV visits was greatest during the months when serum vitamin D level is lowest in Boston.
Little is known about the effects of vitamin D on mineralization of otoconia. On the basis of the recently described association between vitamin D deficiency and BPPV, one could speculate that bone and otoconia share some risk factors for demineralization. An ongoing clinical trial is designed to determine whether treatment with cholecalciferol plus calcium prevents recurrent BPPV. 6 The optimal design of such trials may need to account for both the well-known seasonality of serum vitamin D level in northern and southern latitudes, as well as a possible seasonality of BPPV. Limitations of our study include the fact that we retrospectively considered only the first instance of BPPV. Future investigations could prospectively analyze seasonality of BPPV recurrences in individuals. 
COMMENT & RESPONSE

A Critical Appraisal of Ventilation Tube Insertion in Children With Cleft Palate
To the Editor I read with great interest the article by Smillie et al. 1 However, I found a number of important issues that must be addressed. First, the authors concluded that their findings are the best evidence to measure the effect of cleft lip and/or palate (CLP) on complication rate. Given that several important complications (eg, eardrum perforation) are not analyzed in the study, the uncertain evidence requires further assessment. In the literature, another 2 studies also included age-matched, healthy control children for a comparison of the post-ventilation tube insertion (VTI) complications. 2,3 One controlled prospective study 3 showed that the prognosis of the children with CLP was as favorable as that of those without CLP, while the other study 2 reported contradictory results, with a higher rate of complications in the children with cleft conditions. Hence, I believe the evidence remains inconclusive regarding the difference in the rates of complications.
The authors suggested that patients with CLP should be treated with VTI for otitis media with effusion (OME) in the same way as patients without CLP. Given the retrospective nature and limited generalizability of the study, the conclusions may be arbitrary and could easily be misinterpreted to mean that VTI is a safe procedure in children with CLP. The false sense of security is potentially dangerous because many aspects have not been investigated sufficiently before recommendations could be made on the therapeutic strategy. For instance, attention should be paid to the differences between children with CLP vs those without concerning hearing, speech and language outcomes, middle ear status, and frequency of VTI. 4 I have queries as to the criteria applied to the research participants. The case group in the study is the children with cleft lip "and/or" palate. However, the children with cleft lip only should be excluded given that palatal malformations rather than cleft lip defects play a main role in the formation of OME. The study incorporated both children with OME and those with acute otitis media, which are nevertheless distinct disease entities. For these reasons, it is questionable whether the integrated analysis can reflect the true estimates of the effect of VTI on OME in children with cleft palate.
I believe the study is promising as a foundation for future research, but we should be careful not to overextrapolate the findings to children with cleft palate. If a more definitive interpretation is reached, it would be easier for readers to apply the results in a clinical context.
